CRISPR genome editing is revolutionizing medicine. Rapid market growth, fueled by startups and new therapies, brings ethical ...

Discover how genetic mutations, like BRCA1 and BRCA2, impact cancer risk and personalized treatment strategies.

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children's Hospital of ...

Corteva has vast internal expertise. But it doesn’t have a monopoly on good ideas, says the head of its new Corteva Catalyst ...

CRISPR-Cas has transformed our ability to edit DNA sequences, with broad spectrum applications in agriculture, health, and ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of ...

A Ludwig Cancer Research study has punctured a longstanding assumption about the source of the most common type of DNA ...

Researchers at the Institute of Biotechnology have successfully developed and mastered genome editing technology using the ...

Using a form of CRISPR technology, the ultimate vision of the four-year grant is to create a platform for rapid development of personalized gene-editing therapies for a wide range of rare genetic ...

Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.